Key Points
-
Insulin resistance due to obesity is a primary event in the development of type 2 diabetes. Recent work indicates a central role of adipose tissue dysfunction in linking obesity to insulin resistance.
-
Fatty acids and their derivatives are mediators of insulin resistance in skeletal muscle, probably through deleterious effects on the insulin signalling pathway. Increased exposure of skeletal muscle tissue to elevated fatty acids in rodents and humans impairs insulin-stimulated glucose uptake.
-
The impaired ability of adipose tissue to sequester fatty acids in triglyceride stores results in increasing fatty acid concentrations in the circulation and the exposure of skeletal muscle to these high fatty acid levels. This impairment of adipose function can be caused by a chronic inflammatory state that arises within adipose tissue in obese animals and humans.
-
Inflammatory cytokines, including tumour-necrosis factor-α (TNFα), have profound effects on adipocyte metabolism by impairing triglyceride synthesis and storage, and promoting the hydrolysis and release of triglycerides as free fatty acids. These effects are mediated in part through downregulation of the key adipocyte transcription factor PPARγ (peroxisome proliferator-activated receptor-γ).
-
Recent data implicate lipid-droplet proteins, including newly described CIDE family proteins, in the promotion of triglyceride storage and as significant targets of PPARγ regulation. Through effects on these proteins, downregulation of PPARγ can mediate diminished lipid storage ability of inflamed adipose tissue. Expression of these proteins may be determinants of the differential ability to sequester fat away from the circulation and the propensity of obese humans to develop insulin resistance.
Abstract
Acquired resistance to the action of insulin to stimulate glucose transport in skeletal muscle is associated with obesity and promotes the development of type 2 diabetes. In skeletal muscle, insulin resistance can result from high levels of circulating fatty acids that disrupt insulin signalling pathways. However, the severity of insulin resistance varies greatly among obese people. Here we postulate that this variability might reflect differences in levels of lipid-droplet proteins that promote the sequestration of fatty acids within adipocytes in the form of triglycerides, thereby lowering exposure of skeletal muscle to the inhibitory effects of fatty acids.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Flier, J. S. Obesity wars: molecular progress confronts an expanding epidemic. Cell 116, 337–350 (2004).
Hogan, P., Dall, T. & Nikolov, P. Economic costs of diabetes in the US in 2002. Diabetes Care 26, 917–932 (2003).
Alberti, K. G. The costs of non-insulin-dependent diabetes mellitus. Diabet. Med. 14, 7–9 (1997).
Clee, S. M. & Attie, A. D. The genetic landscape of type 2 diabetes in mice. Endocr. Rev. 28, 48–83 (2007).
Sims, E. A. et al. Endocrine and metabolic effects of experimental obesity in man. Recent Prog. Horm. Res. 29, 457–496 (1973).
Freidenberg, G. R., Reichart, D., Olefsky, J. M. & Henry, R. R. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J. Clin. Invest. 82, 1398–1406 (1988).
Kahn, S. E. The relative contributions of insulin resistance and β-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 46, 3–19 (2003).
Butler, A. E. et al. β-cell deficit and increased β-cell apoptosis in humans with type 2 diabetes. Diabetes 52, 102–110 (2003).
Rhodes, C. J. Type 2 diabetes—a matter of β-cell life and death? Science 307, 380–384 (2005).
Unger, R. H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 44, 863–870 (1995).
Unger, R. H. Lipotoxic diseases. Annu. Rev. Med. 53, 319–336 (2002).
Savage, D. B., Petersen, K. F. & Shulman, G. I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87, 507–520 (2007). A recent review focusing on studies of lipid effects on insulin resistance in human subjects.
Boden, G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46, 3–10 (1997). Demonstrates that infusion of free fatty acids acutely induces insulin resistance in human subjects.
Kelley, D. E., Mokan, M., Simoneau, J. A. & Mandarino, L. J. Interaction between glucose and free fatty acid metabolism in human skeletal muscle. J. Clin. Invest. 92, 91–98 (1993).
Santomauro, A. T. et al. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48, 1836–1841 (1999).
Oakes, N. D. et al. Diet-induced muscle insulin resistance in rats is ameliorated by acute dietary lipid withdrawal or a single bout of exercise: parallel relationship between insulin stimulation of glucose uptake and suppression of long-chain fatty acyl-CoA. Diabetes 46, 2022–2028 (1997).
Goodpaster, B. H., Thaete, F. L., Simoneau, J. A. & Kelley, D. E. Subcutaneous abdominal fat and thigh muscle composition predict insulin sensitivity independently of visceral fat. Diabetes 46, 1579–1585 (1997).
Perseghin, G. et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48, 1600–1606 (1999).
Krssak, M. et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 42, 113–116 (1999).
Szczepaniak, L. S. et al. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Am. J. Physiol. 276, E977–E989 (1999).
Sovik, O., Vestergaard, H., Trygstad, O. & Pedersen, O. Studies of insulin resistance in congenital generalized lipodystrophy. Acta Paediatr. Suppl. 413, 29–37 (1996).
Moitra, J. et al. Life without white fat: a transgenic mouse. Genes Dev. 12, 3168–3181 (1998).
Laustsen, P. G. et al. Lipoatrophic diabetes in Irs1−/−/Irs3−/− double knockout mice. Genes Dev. 16, 3213–3222 (2002).
Shimomura, I. et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev. 12, 3182–3194 (1998).
Arioglu, E., Rother, K. I., Reitman, M. L., Premkumar, A. & Taylor, S. I. Lipoatrophy syndromes: when 'too little fat' is a clinical problem. Pediatr. Diabetes 1, 155–168 (2000).
Oral, E. A. et al. Leptin-replacement therapy for lipodystrophy. N. Engl. J. Med. 346, 570–578 (2002).
Ahima, R. S. & Flier, J. S. Leptin. Annu. Rev. Physiol. 62, 413–437 (2000).
Berg, A. H., Combs, T. P. & Scherer, P. E. ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol. Metab. 13, 84–89 (2002).
Unger, R. H. & Orci, L. Diseases of liporegulation: new perspective on obesity and related disorders. FASEB J. 15, 312–321 (2001).
Rosen, E. D. & Spiegelman, B. M. Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444, 847–853 (2006).
Kalderon, B., Mayorek, N., Berry, E., Zevit, N. & Bar-Tana, J. Fatty acid cycling in the fasting rat. Am. J. Physiol. Endocrinol. Metab. 279, E221–E227 (2000).
Christianson, J. L., Nicoloro, S., Straubhaar, J. & Czech, M. P. Stearoyl CoA desaturase 2 is required for PPARγ expression and adipogenesis in cultured 3T3-L1 cells. J. Biol. Chem. 283, 2906–2916 (2007).
Frayn, K. N. et al. Regulation of fatty acid movement in human adipose tissue in the postabsorptive-to-postprandial transition. Am. J. Physiol. 266, E308–E317 (1994).
Qatanani, M. & Lazar, M. A. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 21, 1443–1455 (2007).
Rajala, M. W. & Scherer, P. E. Minireview: the adipocyte-at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144, 3765–3773 (2003).
Kershaw, E. E. & Flier, J. S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89, 2548–2556 (2004).
Sartipy, P. & Loskutoff, D. J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc. Natl Acad. Sci. USA 100, 7265–7270 (2003).
Xu, H. et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 112, 1821–1830 (2003).
Curat, C. A. et al. From blood monocytes to adipose tissue-resident macrophages: induction of diapedesis by human mature adipocytes. Diabetes 53, 1285–1292 (2004).
Weisberg, S. P. et al. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112, 1796–1808 (2003).
Inouye, K. E. et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 56, 2242–2250 (2007).
Lagathu, C. et al. Long-term treatment with interleukin-1β induces insulin resistance in murine and human adipocytes. Diabetologia 49, 2162–2173 (2006).
Kanda, H. et al. MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity. J. Clin. Invest. 116, 1494–1505 (2006).
Uysal, K. T., Wiesbrock, S. M., Marino, M. W. & Hotamisligil, G. S. Protection from obesity-induced insulin resistance in mice lacking TNF-α function. Nature 389, 610–614 (1997). Strongly suggests a role for an inflammatory cytokine in mediating insulin resistance.
Solinas, G. et al. JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity. Cell Metab. 6, 386–397 (2007).
Harman-Boehm, I. et al. Macrophage infiltration into omental versus subcutaneous fat across different populations: effect of regional adiposity and the comorbidities of obesity. J. Clin. Endocrinol. Metab. 92, 2240–2247 (2007).
Bruun, J. M., Helge, J. W., Richelsen, B. & Stallknecht, B. Diet and exercise reduce low-grade inflammation and macrophage infiltration in adipose tissue but not in skeletal muscle in severely obese subjects. Am. J. Physiol. Endocrinol. Metab. 290, E961–E967 (2006).
Cancello, R. et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes 54, 2277–2286 (2005).
Bouzakri, K. & Zierath, J. R. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-α-induced insulin resistance. J. Biol. Chem. 282, 7783–7789 (2007).
Tang, X. et al. An RNA interference-based screen identifies MAP4K4/NIK as a negative regulator of PPARγ, adipogenesis, and insulin-responsive hexose transport. Proc. Natl Acad. Sci. USA 103, 2087–2092 (2006).
Tesz, G. J. et al. Tumor necrosis factor α (TNFα) stimulates Map4k4 expression through TNFα receptor 1 signaling to c-Jun and activating transcription factor 2. J. Biol. Chem. 282, 19302–19312 (2007).
Shulman, G. I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171–176 (2000).
Biddinger, S. B. & Kahn, C. R. From mice to men: insights into the insulin resistance syndromes. Annu. Rev. Physiol. 68, 123–158 (2006).
Ofei, F., Hurel, S., Newkirk, J., Sopwith, M. & Taylor, R. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 45, 881–885 (1996).
Paquot, N., Castillo, M. J., Lefebvre, P. J. & Scheen, A. J. No increased insulin sensitivity after a single intravenous administration of a recombinant human tumor necrosis factor receptor: Fc fusion protein in obese insulin-resistant patients. J. Clin. Endocrinol. Metab. 85, 1316–1319 (2000).
Kraegen, E. W., Cooney, G. J., Ye, J. M., Thompson, A. L. & Furler, S. M. The role of lipids in the pathogenesis of muscle insulin resistance and β cell failure in type II diabetes and obesity. Exp. Clin. Endocrinol. Diabetes. 109 (Suppl. 2), S189–S201 (2001).Article
Aguirre, V., Uchida, T., Yenush, L., Davis, R. & White, M. F. The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307. J. Biol. Chem. 275, 9047–9054 (2000).
Hirosumi, J. et al. A central role for JNK in obesity and insulin resistance. Nature 420, 333–336 (2002).
Gao, Z. et al. Serine phosphorylation of insulin receptor substrate 1 by inhibitor κB kinase complex. J. Biol. Chem. 277, 48115–48121 (2002).
Griffin, M. E. et al. Free fatty acid-induced insulin resistance is associated with activation of protein kinase C θ and alterations in the insulin signaling cascade. Diabetes 48, 1270–1274 (1999).
Yu, C. et al. Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J. Biol. Chem. 277, 50230–50236 (2002).
Kim, J. K. et al. PKC-θ knockout mice are protected from fat-induced insulin resistance. J. Clin. Invest. 114, 823–827 (2004).
Dresner, A. et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J. Clin. Invest. 103, 253–259 (1999).
Yuan, M. et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293, 1673–1677 (2001).
Hundal, R. S. et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J. Clin. Invest. 109, 1321–1326 (2002).
Um, S. H. et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431, 200–205 (2004).
Senn, J. J. Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes. J. Biol. Chem. 281, 26865–26875 (2006).
Song, M. J., Kim, K. H., Yoon, J. M. & Kim, J. B. Activation of Toll-like receptor 4 is associated with insulin resistance in adipocytes. Biochem. Biophys. Res. Commun. 346, 739–745 (2006).
Suganami, T. et al. Role of the Toll-like receptor 4/NF-κB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler. Thromb. Vasc. Biol. 27, 84–91 (2007).
Shi, H. et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J. Clin. Invest. 116, 3015–3025 (2006).
Tsukumo, D. M. et al. Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes 56, 1986–1998 (2007).
Hannun, Y. A. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269, 3125–3128 (1994).
Shimabukuro, M. et al. Lipoapoptosis in β-cells of obese prediabetic fa/fa rats. Role of serine palmitoyltransferase overexpression. J. Biol. Chem. 273, 32487–32490 (1998).
Summers, S. A., Garza, L. A., Zhou, H. & Birnbaum, M. J. Regulation of insulin-stimulated glucose transporter GLUT4 translocation and Akt kinase activity by ceramide. Mol. Cell. Biol. 18, 5457–5464 (1998).
Powell, D. J., Turban, S., Gray, A., Hajduch, E. & Hundal, H. S. Intracellular ceramide synthesis and protein kinase Cζ activation play an essential role in palmitate-induced insulin resistance in rat L6 skeletal muscle cells. Biochem. J. 382, 619–629 (2004).
Summers, S. A. & Nelson, D. H. A role for sphingolipids in producing the common features of type 2 diabetes, metabolic syndrome X, and Cushing's syndrome. Diabetes 54, 591–602 (2005).
Holland, W. L. et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab. 5, 167–179 (2007).
Turinsky, J., O'Sullivan, D. M. & Bayly, B. P. 1, 2-Diacylglycerol and ceramide levels in insulin-resistant tissues of the rat in vivo. J. Biol. Chem. 265, 16880–16885 (1990).
Adams, J. M. et al. Ceramide content is increased in skeletal muscle from obese insulin-resistant humans. Diabetes 53, 25–31 (2004).
Tamori, Y., Masugi, J., Nishino, N. & Kasuga, M. Role of peroxisome proliferator-activated receptor-g in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 51, 2045–2055 (2002).
Imai, T. et al. Peroxisome proliferator-activated receptor γ is required in mature white and brown adipocytes for their survival in the mouse. Proc. Natl Acad. Sci. USA 101, 4543–4547 (2004).
Zhang, B. et al. Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α. Mol. Endocrinol. 10, 1457–1466 (1996).
Stephens, J. M., Lee, J. & Pilch, P. F. Tumor necrosis factor-α-induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT4 expression without a loss of insulin receptor-mediated signal transduction. J. Biol. Chem. 272, 971–976 (1997).
Ruan, H., Hacohen, N., Golub, T. R., Van Parijs, L. & Lodish, H. F. Tumor necrosis factor-α suppresses adipocyte-specific genes and activates expression of preadipocyte genes in 3T3-L1 adipocytes: nuclear factor-κB activation by TNF-α is obligatory. Diabetes 51, 1319–1336 (2002).
Puri, V., Virbasius, J. V., Guilherme, A. & Czech, M. P. RNAi screens reveal novel metabolic regulators: RIP140, MAP4k4 and the lipid droplet associated fat specific protein (FSP) 27. Acta Physiol. (Oxf.) 192, 103–115 (2008).
Floyd, Z. E. & Stephens, J. M. Interferon-γ-mediated activation and ubiquitin-proteasome-dependent degradation of PPARγ in adipocytes. J. Biol. Chem. 277, 4062–4068 (2002).
Medina, E. A. et al. Tumour necrosis factor-α decreases Akt protein levels in 3T3-L1 adipocytes via the caspase-dependent ubiquitination of Akt. Endocrinology 146, 2726–2735 (2005).
Diradourian, C., Girard, J. & Pegorier, J. P. Phosphorylation of PPARs: from molecular characterization to physiological relevance. Biochimie 87, 33–38 (2005).
Hauser, S. et al. Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation. J. Biol. Chem. 275, 18527–18533 (2000).
Shao, D. et al. Interdomain communication regulating ligand binding by PPAR-γ. Nature 396, 377–380 (1998).
Hu, E., Kim, J. B., Sarraf, P. & Spiegelman, B. M. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARγ. Science 274, 2100–2103 (1996).
Camp, H. S. & Tafuri, S. R. Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase. J. Biol. Chem. 272, 10811–10816 (1997).
Ristow, M., Muller-Wieland, D., Pfeiffer, A., Krone, W. & Kahn, C. R. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. N. Engl. J. Med. 339, 953–959 (1998).
Rangwala, S. M. et al. Genetic modulation of PPARγ phosphorylation regulates insulin sensitivity. Dev. Cell 5, 657–663 (2003).
Feige, J. N. & Auwerx, J. Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol. 17, 292–301 (2007).
Leonardsson, G. et al. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc. Natl Acad. Sci. USA 101, 8437–8442 (2004).
Powelka, A. M. et al. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. J. Clin. Invest. 116, 125–136 (2006).
Wu, Z. et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 92, 829–839 (1998).
Finck, B. N. & Kelly, D. P. PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116, 615–622 (2006).
Large, V., Peroni, O., Letexier, D., Ray, H. & Beylot, M. Metabolism of lipids in human white adipocyte. Diabetes Metab. 30, 294–309 (2004).
Arner, P. Human fat cell lipolysis: biochemistry, regulation and clinical role. Best Pract. Res. Clin. Endocrinol Metab. 19, 471–482 (2005).
Degerman, E., Resjo, S., Landstrom, T. R. & Manganiello, V. Methods to study phosphorylation and activation of the hormone-sensitive adipocyte phosphodiesterase type 3B in rat adipocytes. Methods Mol. Biol. 155, 167–180 (2001).
Granneman, J. G. & Moore, H. P. Location, location: protein trafficking and lipolysis in adipocytes. Trends Endocrinol. Metab. 19, 3–9 (2008).
Zimmermann, R. et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 306, 1383–1386 (2004).
Ryden, M. et al. Comparative studies of the role of hormone-sensitive lipase and adipose triglyceride lipase in human fat cell lipolysis. Am. J. Physiol. Endocrinol. Metab. 292, E1847–E1855 (2007).
Brasaemle, D. L. Thematic review series: adipocyte biology. The perilipin family of structural lipid droplet proteins: stabilization of lipid droplets and control of lipolysis. J. Lipid Res. 48, 2547–2559 (2007).
Ducharme, N. A. & Bickel, P. E. Minireview: lipid droplets in lipogenesis and lipolysis. Endocrinology 149, 942–949 (2008). Summarizes recent developments in the field of lipid-droplet structure and function.
Wellen, K. E. & Hotamisligil, G. S. Obesity-induced inflammatory changes in adipose tissue. J. Clin. Invest. 112, 1785–1788 (2003).
Langin, D. & Arner, P. Importance of TNFα and neutral lipases in human adipose tissue lipolysis. Trends Endocrinol. Metab. 17, 314–320 (2006).
Hotamisligil, G. S., Arner, P., Caro, J. F., Atkinson, R. L. & Spiegelman, B. M. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J. Clin. Invest. 95, 2409–2415 (1995).
Engfeldt, P. & Arner, P. Lipolysis in human adipocytes, effects of cell size, age and of regional differences. Horm. Metab. Res. Suppl. 19, 26–29 (1988).
Czech, M. P. Cellular basis of insulin insensitivity in large rat adipocytes. J. Clin. Invest. 57, 1523–1532 (1976).
Tontonoz, P., Hu, E., Devine, J., Beale, E. G. & Spiegelman, B. M. PPAR γ 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol. Cell. Biol. 15, 351–357 (1995).
Dalen, K. T. et al. Adipose tissue expression of the lipid droplet-associating proteins S3-12 and perilipin is controlled by peroxisome proliferator-activated receptor-γ. Diabetes 53, 1243–1252 (2004).
Wolins, N. E. et al. OXPAT/PAT-1 is a PPAR-induced lipid droplet protein that promotes fatty acid utilization. Diabetes 55, 3418–3428 (2006).
Kadereit, B. et al. Evolutionarily conserved gene family important for fat storage. Proc. Natl Acad. Sci. USA 105, 94–99 (2008).
Puri, V. et al. Fat-specific protein 27, a novel lipid droplet protein that enhances triglyceride storage. J. Biol. Chem. 282, 34213–34218 (2007).
Liang, L., Zhao, M., Xu, Z., Yokoyama, K. K. & Li, T. Molecular cloning and characterization of CIDE-3, a novel member of the cell-death-inducing DNA-fragmentation-factor (DFF45)-like effector family. Biochem. J. 370, 195–203 (2003).
Inohara, N., Koseki, T., Chen, S., Wu, X. & Nunez, G. CIDE, a novel family of cell death activators with homology to the 45 kDa subunit of the DNA fragmentation factor. EMBO J. 17, 2526–2533 (1998).
Puri, V. et al. Cidea: a novel lipid droplet protein associated with insulin sensitivity in humans. Proc. Natl Acad. Sci. USA (in the press).
Brasaemle, D. L., Dolios, G., Shapiro, L. & Wang, R. Proteomic analysis of proteins associated with lipid droplets of basal and lipolytically stimulated 3T3-L1 adipocytes. J. Biol. Chem. 279, 46835–46842 (2004).
Martinez-Botas, J. et al. Absence of perilipin results in leanness and reverses obesity in Leprdb/db mice. Nature Genet. 26, 474–479 (2000).
Nordstrom, E. A. et al. A human-specific role of cell death-inducing DFFA (DNA fragmentation factor-α)-like effector A (CIDEA) in adipocyte lipolysis and obesity. Diabetes 54, 1726–1734 (2005).
Wolins, N. E., Brasaemle, D. L. & Bickel, P. E. A proposed model of fat packaging by exchangeable lipid droplet proteins. FEBS Lett. 580, 5484–5491 (2006).
Perugini, R. A. et al. Metabolic characterization of nondiabetic severely obese patients undergoing Roux-en-Y gastric bypass: preoperative classification predicts the effects of gastric bypass on insulin-glucose homeostasis. J. Gastrointest. Surg. 11, 1083–1090 (2007).
Kim, H. J. et al. Depot-specific regulation of perilipin by rosiglitazone in a diabetic animal model. Metabolism 56, 676–685 (2007).
Smith, R. E. & Horwitz, B. A. Brown fat and thermogenesis. Physiol. Rev. 49, 330–425 (1969).
Nedergaard, J., Bengtsson, T. & Cannon, B. Unexpected evidence for active brown adipose tissue in adult humans. Am. J. Physiol. Endocrinol. Metab. 293, E444–E452 (2007).
Katagiri, H., Yamada, T. & Oka, Y. Adiposity and cardiovascular disorders: disturbance of the regulatory system consisting of humoral and neuronal signals. Circ. Res. 101, 27–39 (2007).
Bartness, T. J. & Song, C. K. Thematic review series: adipocyte biology. Sympathetic and sensory innervation of white adipose tissue. J. Lipid Res. 48, 1655–1672 (2007).
Mootha, V. K. et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet. 34, 267–273 (2003).
Patti, M. E. et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc. Natl Acad. Sci. USA 100, 8466–8471 (2003).
Petersen, K. F. et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300, 1140–1142 (2003).
Petersen, K. F., Dufour, S., Befroy, D., Garcia, R. & Shulman, G. I. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N. Engl. J. Med. 350, 664–671 (2004).
Richardson, D. K. et al. Lipid infusion decreases the expression of nuclear encoded mitochondrial genes and increases the expression of extracellular matrix genes in human skeletal muscle. J. Biol. Chem. 280, 10290–10297 (2005).
Sparks, L. M. et al. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 54, 1926–1933 (2005).
Petersen, K. F. et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. Diabetes 54, 603–608 (2005).
Reznick, R. M. & Shulman, G. I. The role of AMP-activated protein kinase in mitochondrial biogenesis. J. Physiol. 574, 33–39 (2006).
Morino, K., Petersen, K. F. & Shulman, G. I. Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55 (Suppl. 2), S9–S15 (2006).Article
Turner, N. et al. Excess lipid availability increases mitochondrial fatty acid oxidative capacity in muscle: evidence against a role for reduced fatty acid oxidation in lipid-induced insulin resistance in rodents. Diabetes 56, 2085–2092 (2007).
Koves, T. R. et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45–56 (2008).
Acknowledgements
We thank the members of our laboratory group for excellent discussions on the issues addressed here. We acknowledge funding for our studies covered here by the National Institutes of Health (grants DK030648 and DK030898), including the University of Massachusetts Medical School Diabetes and Endocrinology Research Center (DK32520).
Author information
Authors and Affiliations
Corresponding author
Related links
Glossary
- White adipose tissue
-
The predominant fat storage tissue in animals, consisting mostly of adipocytes but also other cell types such as mast cells and macrophages. It is distributed in a number of subcutaneous and visceral depots.
- Free fatty acid
-
A carboxylic acid with aliphatic chains of 4–28 carbons, which can be esterified with glycerol to form triglycerides, the main stored form of lipid.
- Acipimox
-
A nicotinic-acid analogue that reduces plasma and intracellular fatty acid levels by suppressing lipolysis.
- Adipokine
-
A cytokine or hormone that is secreted by adipose tissue.
- Lipodystrophy
-
Abnormality of the adipose tissue that is associated with total or partial loss of body fat. This might have a genetic origin in humans or occur as a result of other diseases.
- MAP4K4
-
(Mitogen-activated protein kinase kinase kinase kinase-4). A mammalian Ser/Thr protein kinase related to Saccharomyces cerevisiae Sterile-20 (STE20).
- Omental adipose tissue
-
The fat depot found within the peritoneum, in close association with the stomach and other internal organs.
- Diacylglycerol
-
A molecule that consists of two fatty acid chains esterified with glycerol, produced by the cleavage of membrane phosphatidylinositol 4,5-bisphosphate. Diacylglycerol functions as a signalling molecule by activating protein kinase C.
- Salicylates
-
A group of derivatives of salicylic acid, including aspirin and acetylsalicylic acid, which are widely used as analgesics and anti-inflammatory medications.
- Toll-like receptors
-
Cell-surface receptors that recognize a wide variety of molecules, primarily markers of foreign organisms including bacteria. Main functions include the activation of the innate immune response in infection.
- Sphingolipids
-
Lipids that consist of the aliphatic alcohol sphingosine linked to a fatty acid chain and a variety of head groups. Sphingolipids include ceramides, sphingomyelin and glycosphingolipids.
- Glucocorticoids
-
Steroid hormones, including cortisol, that are produced in the adrenal gland. These hormones have potent effects on energy metabolism in the liver, fat and elsewhere.
- C/EBPα
-
(CCAAT/enhancer-binding protein-α). A transcription factor that has a key role in the differentiation of adipocytes.
- Adrenoreceptors
-
A class of G-protein-coupled receptors activated by catecholamines. Adrenoreceptors in white fat stimulate lipolysis in response to catecholamines.
- Catecholamines
-
A group of amine hormones including adrenaline and noradrenaline. These are produced by the adrenal gland in response to starvation and other stresses.
- Perilipin
-
A main protein component of adipocyte lipid droplets, which surrounds the lipids and participates in the regulation of lipolysis.
- Rosiglitazone
-
An antidiabetic drug, one of several thiazolidinediones (TZDs) used therapeutically. Many TZDs are known to be high-affinity ligand activators of PPARγ.
- HOMA-IR
-
(Homeostatic model assessment of insulin resistance). An estimation of the degree of insulin resistance that is calculated from clinical measurement of fasting blood glucose and insulin levels.
Rights and permissions
About this article
Cite this article
Guilherme, A., Virbasius, J., Puri, V. et al. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 9, 367–377 (2008). https://doi.org/10.1038/nrm2391
Issue Date:
DOI: https://doi.org/10.1038/nrm2391